COPD Clinical Trials

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition that affects millions of people worldwide. Current treatments help manage COPD symptoms, but many patients still experience exacerbations and declining lung function amid disease progression. COPD clinical trials are helping to advance available treatment options and drive better outcomes.

Join a Study

Current treatment for chronic obstructive pulmonary disease

COPD is characterized by a persistent airflow limitation. This can result in symptoms like shortness of breath, chronic cough, and moderate or severe exacerbations.

The most common treatment for COPD symptoms is bronchodilator therapy. Bronchodilators are medications that work by relaxing airway muscles to improve airflow and provide relief.

Inhaled corticosteroids (ICS) are often used in conjunction with bronchodilators. The medical community has found some patients, especially those with a history of severe COPD exacerbations, respond best when bronchodilator therapy is combined with other add-on therapies.

Key focus areas in modern COPD clinical trials

Biologics
Triple Inhalers
Combination Vaccines

Biologics

Biologics are designed to target specific pathways in the immune system, offering personalized treatment options for patients who may not respond to conventional COPD therapies. Studies have shown the efficacy of biologics in reducing exacerbations and improving lung function in COPD patients.

Triple Inhalers

Triple inhalers have shown promising results in helping patients manage their COPD and severe asthma. Studies have indicated that these inhalers can reduce the risk of cardiovascular complications in COPD patients, which ongoing COPD clinical trials will continue to investigate.

Combination Vaccines

COPD patients are at higher risk for severe respiratory infections, including influenza, RSV, and pneumonia. Clinical trials are investigating combination vaccines that offer broader protection in a single shot, which could improve vaccination rates and reduce COPD-related complications.

RDI’s experience in COPD clinical trials

With over 30 years of experience, Remington-Davis (RDI) is a trusted leader in COPD clinical research. We have successfully conducted more than 60 COPD clinical trials, working closely with sponsors, CROs, and investigators to manage high-quality studies that fuel advancement.

Backed by a patient-centric approach, we strive to make trial participation as comfortable and as convenient as possible. We offer flexible scheduling, transportation services, and a 7,500 square-foot facility equipped with at-home amenities like Wi-Fi, beverages, snacks, and more. It’s variables like these that help us maintain a 98% patient retention rate.

At RDI, we are committed to advancing COPD research while fostering a supportive, patient-centered experience—because better trials mean better treatments for everyone. Be a part of our next medical breakthrough.

Be a part of our next COPD medical breakthrough.

View Enrolling Studies

Who can participate in a COPD clinical trial

Mild, moderate, or severe COPD patients, including those with chronic bronchitis or emphysema, may qualify for clinical trials based on their medical history, current treatment plan, and disease severity. Healthy volunteers are essential as well to ensure the clinical efficacy of new chronic obstructive lung disease therapies.

Frequently asked questions

How do COPD trials contribute to research on respiratory diseases?

COPD clinical trials play a role in advancing treatment options for respiratory diseases like biologics, while exploring the relationship between COPD and other conditions like pulmonary hypertension and interstitial lung disease. These findings help improve therapies and patient outcomes.

Are all COPD clinical trials placebo-controlled studies?

Not all COPD clinical trials use a placebo-controlled study design. Some trials compare a new treatment to a standard therapy, while others evaluate different drug combinations or disease management strategies. The type of study depends on the primary objective of the research.

What are the different phases of COPD clinical trials?

COPD clinical trials progress through four phases to evaluate a treatment’s safety, effectiveness, and long-term impact. Phase I trials are small studies focused on determining a new drug’s safety, dosage, and potential side effects in humans. Phase II is where researchers assess its effectiveness and optimal dosing in a larger group of participants. Phase III trials are large-scale studies involving hundreds to thousands of COPD patients, comparing the investigational treatment to standard therapies or a placebo. Phase IV studies continue to track long-term safety and effectiveness in a broader population.